Open AccessAnticoagulant Reversal in Gastrointestinal Bleeding: Review of Treatment Guidelines
Author(s) -
Truman J. Milling,
Majed A. Refaai,
Neil Sengupta
Publication year - 2021
Publication title -
digestive diseases and sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 124
eISSN - 1573-2568
pISSN - 0163-2116
DOI - 10.1007/s10620-020-06728-y
Subject(s) - medicine , anticoagulant , prothrombin complex concentrate , warfarin , hemostasis , guideline , intensive care medicine , gastrointestinal bleeding , dabigatran , coagulopathy , coagulation testing , coagulation , atrial fibrillation , pathology
Patients receiving anticoagulant therapies, such as vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs), commonly experience gastrointestinal (GI) bleeding as a complication and may require anticoagulant reversal prior to endoscopic treatment. Anticoagulant reversal agents include prothrombin complex concentrates (PCCs; including 3 or 4 coagulation factors), plasma, vitamin K, and target-specific DOAC reversal agents (e.g., idarucizumab and andexanet alfa).